PD-1/PD-L1-IN-23

• CAT Number: I044138
• CAS Number: 2597056-04-5
• Molecular Formula: C32H30BrCl2N3O6
• Molecular Weight: 703.41
• Purity: ≥95%
• Synonyms: ethyl 2-[[2-(2,1,3-benzoxadiazol-5-ylmethoxy)-4-[(2-bromo-3-phenylphenyl)methoxy]-5-chlorophenyl]methylamino]-3-hydroxypropanoate;hydrochloride
• IUPAC Name: ethyl (2R)-2-[[2-(2,1,3-benzoxadiazol-5-ylmethoxy)-4-[(2-bromo-3-phenylphenyl)methoxy]-5-chlorophenyl]methylamino]-3-hydroxypropanoate;hydrochloride
• InChI: InChI=1S/C32H29BrClN3O6.ClH/c1-2-40-32(39)28(17-38)35-16-23-14-25(34)30(15-29(23)41-18-20-11-12-26-27(13-20)37-43-36-26)42-19-22-9-6-10-24(31(22)33)21-7-4-3-5-8-21;/h3-15,28,35,38H,2,16-19H2,1H3;1H/t28-;/m1./s1
• InChIKey: RDOKDKCLEBIFLB-LNLSOMNWSA-N
• SMILES: CCOC(=O)[C@@H](CO)NCC1=CC(=C(C=C1OCC2=CC3=NON=C3C=C2)OCC4=C(C(=CC=C4)C5=CC=CC=C5)Br)Cl.Cl

PD-1/PD-L1-IN-23（Cat No.:I044138）is a small-molecule inhibitor that disrupts the interaction between Programmed Cell Death Protein 1 (PD-1) and its ligand PD-L1, a key immune checkpoint pathway exploited by tumors to evade immune surveillance. By blocking PD-1/PD-L1 binding, this compound restores T-cell activation and promotes antitumor immune responses, making it valuable in cancer immunotherapy research. PD-1/PD-L1-IN-23 is studied for its potential to enhance immune checkpoint blockade in various cancers, including melanoma, lung, and colorectal cancers. It offers an alternative to monoclonal antibodies, with advantages in oral availability and intracellular target accessibility.